糖尿病性腎臓病市場：薬剤クラス別、投与経路別、流通チャネル別、地域別

世界の糖尿病性腎臓病市場は、2024年には30億3,000万米ドルと推定され、2031年には42億1,000万米ドルに達すると予測され、2024年から2031年までのCAGRは4.8%です。

図1.糖尿病性腎臓病市場シェア（%）、地域別、2024年

糖尿病性腎臓病（DKD）は、長年の糖尿病が原因で腎臓が損傷を受ける疾患です。糖尿病による高血糖が長期化すると、腎臓の細い血管だけでなく、腎臓内のろ過装置（糸球体）にもダメージを与えます。糸球体の損傷は腎臓の機能を低下させ、効果的にコントロールできなければ腎不全につながる可能性があります。世界の糖尿病有病率の増加に伴い、糖尿病性腎臓病治療市場は近い将来安定的に成長すると予測されます。

市場力学：

世界の糖尿病性腎臓病市場は、世界の糖尿病および肥満の有病率の上昇により、著しい成長を遂げています。市場促進要因としては、慢性腎臓病に罹患しやすい高齢者人口の増加、糖尿病性腎臓病の早期診断・治療に対する意識の高まり、糖尿病性腎臓病を治療する新薬の米国FDA認可の増加などが挙げられます。しかし、腎不全治療に伴う高額な費用や低所得地域における疾患に対する認識不足などの要因が、市場成長の妨げとなる可能性があります。安全性プロファイルを改善し、より効能の高い薬剤を開発するための継続的な研究開発努力は、市場企業に有利な機会を提供します。腎臓病治療に対する世界各国政府の医療支出の増加は、予測期間中に良好な事業環境を生み出すと予想されます。

本調査の主な特徴

• 本レポートでは、世界の糖尿病性腎臓病市場を詳細に分析し、2023年を基準年とした予測期間（2024-2031年）の市場規模および複合年間成長率（CAGR%）を掲載しています。
• また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場に対する魅力的な投資提案のマトリックスについて解説しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
• 企業のハイライト、製品ポートフォリオ、主要なハイライト、財務実績、戦略などのパラメータに基づいて、世界の糖尿病性腎臓病市場の主要企業をプロファイルしています。
• このレポートからの洞察は、マーケティング担当者や企業の経営陣が、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことを可能にします。
• 世界の糖尿病性腎臓病市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。
• 利害関係者は、世界の糖尿病性腎臓病市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• Coherent Opportunity Map（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 市場機会
• 影響分析
• 市場動向
• 最近の動向
• 買収と提携のシナリオ
• テクノロジーの概要
• 規制シナリオ
• 価格分析
• PEST分析

第4章 世界の糖尿病性腎臓病市場- コロナウイルス（COVID-19）パンデミックの影響

• 全体的な影響
• 政府の取り組み
• COVID-19市場への影響

第5章 世界の糖尿病性腎臓病市場、薬剤クラス別、2019年-2031年

• アンジオテンシン受容体拮抗薬（ARB）
• カルシウムチャネル遮断薬
• 抗酸化炎症調節剤
• アンジオテンシン変換酵素（ACE）阻害剤
• その他

第6章 世界の糖尿病性腎臓病市場、投与経路別、2019年-2031年

• 経口
• 非経口

第7章 世界の糖尿病性腎臓病市場、流通チャネル別、2019年-2031年

• 病院薬局
• 小売薬局
• オンライン薬局

第8章 世界の糖尿病性腎臓病市場、地域別、2019年-2031年

• 北米
• 米国
• カナダ
• ラテンアメリカ
• ブラジル
• メキシコ
• アルゼンチン
• その他ラテンアメリカ
• 欧州
• 英国
• ドイツ
• イタリア
• フランス
• スペイン
• ロシア
• その他欧州
• アジア太平洋地域
• 中国
• インド
• 日本
• ASEAN
• オーストラリア
• 韓国
• その他アジア太平洋地域
• 中東
• 湾岸協力会議
• イスラエル
• その他中東
• アフリカ
• 北アフリカ
• 中央アフリカ
• 南アフリカ

第9章 競合情勢

• 企業プロファイル
  • AstraZeneca
  • Boehringer Ingelheim
  • Janssen Pharmaceuticals
  • Bristol Myers Squibb
  • GSK
  • Novo Nordisk
  • Eli Lilly and Company
  • Merck &Co.
  • Sanofi
  • AbbVie
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Lupin
  • Aurobindo Pharma
  • Takeda Pharmaceutical Company Limited
  • Biogen
  • Vertex Pharmaceuticals Incorporated

第10章 アナリストの見解

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

第11章 参考文献と調査手法

• 参考文献
• 調査手法

Global diabetic kidney disease market is estimated to be valued at USD 3.03 Bn in 2024 and is expected to reach USD 4.21 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.8% from 2024 to 2031.

Figure 1. Diabetic Kidney Disease Market Share (%), By Region, 2024

Diabetic kidney disease (DKD) is a condition in which the kidneys are damaged due to long-standing diabetes. Over time, high blood sugar from diabetes can damage both the small blood vessels in the kidneys as well as the filtering units (glomeruli) within the kidneys. Damage to the glomeruli can reduce kidney function and may lead to kidney failure, if not controlled effectively. With increasing prevalence of diabetes globally, the market for treatments of diabetic kidney disease is projected to grow steadily in the near future.

Market Dynamics:

Global diabetic kidney disease market is witnessing significant growth due to rising prevalence of diabetes and obesity worldwide. Some of the key drivers fueling the market growth include growing geriatric population who are more susceptible to chronic kidney diseases, rising awareness about early diagnosis and treatment of DKD, and increasing U.S. FDA approvals of novel drugs to treat DKD. However, factors such as high costs associated with kidney failure treatments and lack of diseases awareness in low-income regions can hamper the market growth. Ongoing R&D efforts to develop more efficacious drugs with improved safety profiles provide lucrative opportunities for market players. Increasing health expenditures of governments worldwide on kidney care is anticipated to create a positive business environment during the forecast period.

Key Features of the Study:

• This report provides in-depth analysis of the global diabetic kidney disease market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global diabetic kidney disease market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study includes AstraZeneca, Boehringer Ingelheim, Janssen Pharmaceuticals, Bristol Myers Squibb, GSK, Novo Nordisk, Eli Lilly and Company, Merck & Co., Sanofi, AbbVie, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Lupin, Aurobindo Pharma, Takeda Pharmaceutical Company Limited, Biogen, and Vertex Pharmaceuticals Incorporated.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global diabetic kidney disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global diabetic kidney disease market.

Detailed Segmentation-

• Drug Class:
  • Angiotensin Receptor Blockers (ARBs)
  • Calcium Channel Blockers
  • Antioxidant Inflammation Modulator
  • Angiotensin-Converting Enzyme (ACE) Inhibitors
  • Others
• Route of Administration:
  • Oral
  • Parenteral
• Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • AstraZeneca
  • Boehringer Ingelheim
  • Janssen Pharmaceuticals
  • Bristol Myers Squibb
  • GSK
  • Novo Nordisk
  • Eli Lilly and Company
  • Merck & Co.
  • Sanofi
  • AbbVie
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Lupin
  • Aurobindo Pharma
  • Takeda Pharmaceutical Company Limited
  • Biogen
  • Vertex Pharmaceuticals Incorporated

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Recent Developments
• Acquisitions and Partnerships Scenario
• Technology Overview
• Regulatory Scenario
• Pricing Analysis
• PEST Analysis

4. Global Diabetic Kidney Disease Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the market

5. Global Diabetic Kidney Disease Market, By Drug Class, 2019 - 2031, (USD BN)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Angiotensin Receptor Blockers (ARBs)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
• Calcium Channel Blockers
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
• Antioxidant Inflammation Modulator
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
• Angiotensin-Converting Enzyme (ACE) Inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

6. Global Diabetic Kidney Disease Market, By Route of Administration, 2019 - 2031, (USD BN)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
• Parenteral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

7. Global Diabetic Kidney Disease Market, By Distribution Channel, 2019 - 2031, (USD BN)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

8. Global Diabetic Kidney Disease Market, By Region, 2019 - 2031, (USD BN)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2019-2031
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD BN)
• North Africa
• Central Africa
• South Africa

9. Competitive Landscape

• Company Profiles
  • AstraZeneca
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Market Strategies
  • Boehringer Ingelheim
  • Janssen Pharmaceuticals
  • Bristol Myers Squibb
  • GSK
  • Novo Nordisk
  • Eli Lilly and Company
  • Merck & Co.
  • Sanofi
  • AbbVie
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Lupin
  • Aurobindo Pharma
  • Takeda Pharmaceutical Company Limited
  • Biogen
  • Vertex Pharmaceuticals Incorporated

10. Analyst View

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact